Salute e Benessere

Essity awarded supplier engagement leader by CDP for sixth consecutive year

Essity is dedicated to fostering strong partnerships to collectively reduce Scope 3 related carbon emissions, including sourced key raw materials, by 35% by 2030. For 2024, Essity reported Scope 3 emissions reduction of 21%. Essity is dedicated to fostering strong partnerships to collectively reduce Scope 3 related carbon emissions, including sourced key raw materials, by 35% by 2030. For 2024, Essity reported Scope 3 emissions reduction of 21%. "Our approach to supplier collaboration is...
PR Newswire
08/07/2025

UAE Approves BioAro’s Longevity+ Supplement, Signaling Major Market Potential in…

With a patent-pending formula and international expansion underway, BioAro positions itself as a front-runner in the multi-billion-dollar longevity and wellness sector BioAro has announced the launch of its first nutraceutical product under its new supplement line: Longevity+™, a patent-pending, scientifically formulated capsule designed to support healthy aging through synergistic multi-molecule integration. With approvals already secured in the United Arab Emirates (UAE), BioAro is now...
Nasdaq GlobeNewswire
08/07/2025

Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer

"We are very pleased to welcome Dr Philipson to the executive management team as CMO. He brings invaluable experience in the area of drug development, from first-in-human to Phase 3, and post-approval studies; with expertise across rare diseases, inflammation and oncology, which will be critical as we prepare for the next phase of our development," said CEO Renée Aguiar-Lucander. "We are very pleased to welcome Dr Philipson to the executive management team as CMO. He brings…
PR Newswire
08/07/2025

AB Science announces the successful completion of a EUR 1.925 million private…

PRESS RELEASEAB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.925 MILLION PRIVATE PLACEMENTParis, July 8, 2025, 8am AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors (the “ Private Placement ”).The Private Placement is not subject to a prospectus requiring an approval from the French...
Nasdaq GlobeNewswire
08/07/2025

Swissmedic approves IFINWIL® (eflornithine) for children diagnosed with…

"By collaborating with international regulatory partners through Project Orbis, we are advancing our strategy to broaden access to innovative therapies for paediatric patients in Europe and ANZ." said Dr David Gillen, Chief Medical Officer at Norgine. "At Norgine, we're proud to take on some of the most complex disease areas, driven by our mission to deliver meaningful treatments where they're needed most." "By collaborating with international regulatory partners through…
PR Newswire
08/07/2025

Independent Meta-Analysis Shows SkylineDx's Merlin CP-GEP Assay Accurately…

"Merlin CP-GEP provides valuable clinical information on a patient's risk of sentinel-node metastasis and should therefore be considered as part of current standards of care in patients with clinically node-negative cutaneous melanomas ≤4.0 mm in thickness," said Associated Professor, Chair of Melanoma Surgical Oncology at Melanoma Institute Australia and Principal Investigator Alexander C.J. van Akkooi, MD, PhD, FRACS. "The study showed that Merlin's CP-GEP model is an effective…
PR Newswire
08/07/2025

Basilea receives USD 39 million funding under BARDA agreement to continue to…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed...
Nasdaq GlobeNewswire
08/07/2025

Novartis receives approval for first malaria medicine for newborn babies and…

Coartem ®(artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infantsRapid approvals in eight African countries now expected under a special global health scheme run by Swiss agency for therapeutic products (Swissmedic)Novartis plans to introduce infant-friendly Coartem Baby on largely not-for-profit basis to increase access in areas where malaria is endemic Basel, July 8, 2025– Novartis today announced Coartem ®...
Nasdaq GlobeNewswire
08/07/2025

Traumatic Brain Injury Market to Expand at a CAGR of 10.9% During the Study…

Key Takeaways from the Traumatic Brain Injury Market Report Key Takeaways from the Traumatic Brain Injury Market Report Discover more about the mild traumatic brain injury treatment market @ Traumatic Brain Injury Medication Traumatic Brain Injury Market Dynamics The traumatic brain injury market dynamics are expected to change in the coming years. Decades of innovation have led topowerful diagnostic toolslike modern CT scanners and MRI machines, which can detect...
PR Newswire
07/07/2025

BIOVAXYS ENGAGES ENCLAVE CAPITAL LLC TO ACT AS AN AGENT IN BROKERED PRIVATE…

Upon successful closing of the Offering, Enclave will receive a cash fee equal to 8% of the total proceeds received by the Company from Enclave investors (the "Offering Fee"). In addition to the Offering Fee, the Company will pay Enclave a cash fee of $10,000. Upon successful closing of the Offering, Enclave will receive a cash fee equal to 8% of the total proceeds received by the Company from Enclave investors (the " Offering Fee "). In addition to the Offering Fee, the…
PR Newswire
07/07/2025

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter…

Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning with regulatory status in the US and other major marketsMedicinal product classification supports unified global regulatory classification, facilitating future global strategies and filingsNew composition of matter patent for JNJ-1900 (NBTXR3) filed by Nanobitotix PARIS and CAMBRIDGE, Mass., July07, 2025(GLOBE NEWSWIRE) --...
Nasdaq GlobeNewswire
07/07/2025

Inventiva receives $10 million milestone payment from CTTQ

Daix (France), New York City (New York, United States), July 7, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (“CTTQ”), a subsidiary of Sino Biopharm. This milestone payment...
Nasdaq GlobeNewswire
07/07/2025

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNTAND NEW NUMBER OF SHARES Ghent, Belgium, 7 July 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of the exercise of 30,000 GEM Warrants (as defined below) by GEM Global Yield LLC SCS (" GEM "), the Company's share capital has increased on…
Nasdaq GlobeNewswire
07/07/2025

Ipsen - Half year statement - 2025 06 30

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF PARIS, 07 JULY 2025- Ipsen (Euronext: IPN; ADR: IPSEY) announced today that under the liquidity agreement entrusted by IPSEN S.A. to NATIXIS ODDO BHF, as of June 30, 2025, the following resources were included to the dedicated liquidity account: 38,030 shares €1,320,416.64 It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account: ...
Nasdaq GlobeNewswire
07/07/2025

Cervical Cancer Treatment Market Size is Expected to Reach USD 14.91 Billion by…

The treatment options for cervical cancer include surgery, radiation, chemotherapy, and combinations of these therapies, depending on the stage and spread of the cancer. Radiation therapy, often combined with chemotherapy, is the primary treatment for cervical cancer that has spread beyond the cervix. Surgery, such as a radical trachelectomy, may be used for localized and early-stage cancers. The treatment options for cervical cancer include surgery, radiation, chemotherapy, and combinations…
PR Newswire
07/07/2025

mRNA Sequencing Market Size to Hit USD 4.02 billion by 2031, Growing at 13.6%…

The mRNA sequencing market analysis focuses on an array of products (instruments, consumables, etc.) and services required in various types of sequencing methods, which are expected to contribute to its strength in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities. The mRNA sequencing market analysis focuses on an array of products (instruments, consumables, etc.) and services required in various types of sequencing methods, which…
PR Newswire
07/07/2025

Procedure Trays Market Size Projected to Exceed USD 49.32 Billion by 2031 at a…

The procedure trays market analysis is derived by considering advancements made, which include customized procedure trays and integration with RFID and barcoding. These advancements are expected to accelerate the market growth in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities. The procedure trays market analysis is derived by considering advancements made, which include customized procedure trays and integration with RFID and…
PR Newswire
07/07/2025

Lutris Pharma Presents Additional Positive Data from Its Phase 2 Trial of LUT014…

"EGFR inhibitors, like cetuximab and panitumumab, are critical components of cancer therapy, but their effectiveness is often compromised by skin toxicities that can lead to dose modifications or treatment discontinuation," said Benjamin W. Corn, M.D., Chief Medical Officer of Lutris Pharma. "LUT014 is designed to mitigate these toxicities by restoring downstream signaling in skin cells disrupted by EGFR inhibition. In our clinical trial, the high dose of LUT014 demonstrated…
PR Newswire
07/07/2025

Biochip Market to Reach USD 17.99 Billion by 2030 -- Driven by Diagnostics…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-6N8900/Global_Biochip_Market Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-6N8900/Global_Biochip_Market Major Factors Driving the Growth of Biochip Market: The global biochip market is poised for significant growth, driven by increasing demand for rapid diagnostics, personalized medicine, and high-throughput research tools. As healthcare shifts toward precision-based...
PR Newswire
07/07/2025

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic…

Click here to view the custom infographic of the Calidi Biotherapeutics Inc. editorial. Clickhere to view the custom infographic of the Calidi Biotherapeutics Inc. editorial. Sustained Investment in Research, Development Cancer remains one of the most devastating health challenges facing the globe today, responsible for about one in six deaths worldwide ( https://ibn.fm/ZzZHC ). The most common cancer types worldwide include lung cancer (accounting for around 2.2 million new cases...
PR Newswire
07/07/2025

Osteotec Strengthens UK Spine Portfolio with Exclusive Ulrich Medical…

The agreement represents a strategic alignment between two companies committed to enhancing surgical performance and delivering better outcomes for patients requiring complex spinal interventions, providing Ulrich Medical's world-renowned implant systems for cervical, thoracic and lumbar applications to surgeons throughout the NHS and private healthcare sectors. The agreement represents a strategic alignment between two companies committed to enhancing surgical performance and delivering…
PR Newswire
07/07/2025

Doctors Are Being Outpaced by AI-Powered Algorithms -- Here's What It Means for…

The global AI in healthcare market is on pace to exceed $110 billion by 2030, expanding at a compound annual growth rate of 38.6%, according to MarketsandMarkets. Looking further ahead, Accenture estimates AI could unlock an additional $461 billion in value by 2035, as the healthcare sector approaches $2.26 trillion. These projections underscore how AI is reshaping everything from patient care and diagnostics to infrastructure and financial strategy across the industry. Theglobal AI in...
PR Newswire
07/07/2025

Morphic Medical Announces CE Mark for RESET® Endoscopic Device Therapy

Many patients with obesity and T2D have poor glycemic control despite diet, lifestyle management, and medications. Although Roux-en-Y gastric bypass can be highly effective, it is an invasive and irreversible surgical procedure. RESET is a novel duodenal-jejunal bypass liner (DJBL) which is implanted endoscopically into the upper part of the small intestine, left in place for up to 9 months, and then removed endoscopically. The liner provides a physical barrier between receptors in the…
PR Newswire
07/07/2025

Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for…

HCC is the most common form of liver cancer in adults in the U.S., according to the American Cancer Society. Radioembolization–commonly referred to as selective internal radiation therapy (SIRT)–with SIR-Spheres® uses personalized dosimetry to deliver the optimal dose of radiation directly to tumors in patients with HCC. This approval gives clinicians expanded flexibility in selecting a liver-directed therapy that aligns with patient-specific needs and treatment goals. HCC is the most common...
PR Newswire
07/07/2025
Altri  Comunicati